Kidney cancer: Past, present, and future

Urologic Oncology: Seminars and Original Investigations

Volumn 25, Issue 3, 2007, Pages 188-195

  Novick, Andrew C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; SORAFENIB; SUNITINIB; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL TRIAL; FOLLOW UP; GENE MUTATION; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KIDNEY CANCER; KIDNEY CARCINOMA; METASTASIS; NEPHRON SPARING SURGERY; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MEDICAL ONCOLOGY;

EID: 34247592505     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2007.03.006     Document Type: Article

References (40)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Chow W.H., Devesa S.S., Warren J.L., et al. Rising incidence of renal cell cancer in the United States. JAMA 281 (1999) 1628-1631
3. Cohen H.T., and McGovern F.J. Renal cell carcinoma. NEJM 353 (2005) 2477-2490
4. Campbell S.C., Novick A.C., and Bukowski R.M. Renal tumors. In: Wein A.J., Kavoussi L.R., Novick A.C., et al. (Eds). Campbell-Walsh Urology. 3rd ed. (2007), Saunders/Elsevier, Philadelphia (PA) 1567-1637
5. Kim W.Y., and Kaelin W.G. The role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
6. Kovacs G., Akhtar M., Beckwith B.J., et al. The Heidelberg classification of renal cell tumors. J Pathol 183 (1997) 131-133
7. Lane B.R., Rini B.I., Novick A.C., et al. Targeted molecular therapy for renal cell carcinoma. Urology 69 (2007) 3-10
8. Frank I., Blute M.L., Cheville J.C., et al. An outcome prediction model for patients with clear cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade, and necrosis: The SSIGN score. J Urol 168 (2002) 2395-2400
9. Sorbellini M., Kattan M.W., Snyder M.E., et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173 (2005) 48-51
10. Zisman A., Pantuck A.J., Dorey F., et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19 (2001) 1649-1657
11. Kim H.L., Seligson D., Liu X., et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 10 (2004) 5464-5471
12. Lane B., Kattan M., and Novick A.C. Prediction models of renal cell carcinoma. AUA Update Series Vol 25 (2006) Lesson 7
13. Chawla S.N., Crispen P.L., Hanlon A.L., et al. The natural history of observed enhancing renal masses: Meta-analysis and review of the world literature. J Urol 175 (2006) 425-431
14. Permpongkosol S., Chan D.Y., Link R.E., et al. Long-term survival analysis after laparoscopic radical nephrectomy. J Urol 174 (2005) 1222-1225
15. Hollenbeck B.K., Taub D.A., Miller D.C., et al. National utilization trends of partial nephrectomy for renal cell carcinoma: A case of underutilization?. Urology 67 (2006) 254-259
16. Novick A.C. Nephron-sparing surgery for renal cell carcinoma. Annu Rev Med 53 (2002) 393-407
17. Leibovich B.C., Blute M.L., Cheville J.C., et al. Nephron-sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J Urol 171 (2004) 1066-1070
18. Patard J.J., Shvarts O., Lam J.S., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol 171 (2004) 2181-2185
19. Mitchell R.E., Gilbert S.M., Murphy A.M., et al. Partial nephrectomy and radical nephrectomy offer similar cancer outcomes in renal cortical tumors 4 cm or larger. Urology 67 (2006) 260-264
20. Campbell S.C., and Novick A.C. Expanding the indications for elective partial nephrectomy: Is this advisable?. Eur Urol 49 (2006) 952-954
21. Clark P., Schover L., Uzzo R., et al. Quality of life and psychological adaptation following surgical treatment for localized renal cell carcinoma: Impact of the amount of remaining renal tissue. Urology 57 (2001) 252-256
22. Novick A.C., Gephardt G., Guz B., et al. Long-term follow-up after partial removal of a solitary kidney. NEJM 10 (1991) 1058-1062
23. Novick A.C., and Schreiber M.J. The effect of angiotensin converting enzyme inhibition on nephropathy in patients with a remnant kidney. Urology 46 (1995) 785-789
24. Lau W.K., Blute M.L., Weaver A.L., et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc 75 (2000) 1236-1242
25. McKienan J., Simmons R., Katz J., et al. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 59 (2002) 816-820
26. Huang W.C., Levey A.S., Serio A.M., et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumors: A retrospective cohort study. Lancet Oncol 7 (2006) 735-740
27. Fergany A.F., Hafez K.S., and Novick A.C. Long-term results of nephron-sparing surgery for localized renal cell carcinoma: 10-year follow-up. J Urol 163 (2000) 442-444
28. Fergany A.F., Saad I.R., Woo L., et al. Open partial nephrectomy for tumor in a solitary kidney: Experience with 400 cases. J Urol 175 (2006) 1630-1633
29. Gill I., Matin S., Desai M., et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol 170 (2003) 64-68
30. Hegarty N.J., Gill I.S., Desai M.M., et al. Probe-ablative nephron-sparing surgery: Cryoablation vs. radiofrequency ablation. Urol 68 Suppl 1 (2006) 7-13
31. Hegarty N., Gill I., Kaouk J.H., et al. Renal cryoablation: 5-year outcomes. J Urol 175 (2006) 351
32. Illing R., Leslie T.A., Kennedy J.E., et al. High-intensity focused ultrasound for the treatment of small renal tumors: The Oxford experience. J Urol 175 (2006) 236-237
33. Kohrmann K.U., Michael M.S., Gaa J., et al. High intensity focused ultrasound as noninvasive therapy for multifocal renal cell carcinoma: Case study and review of the literature. J Urol 167 (2002) 2397-2403
34. Ponsky L.E., Novick A.C., Crownover R., et al. The initial evaluation of cyberknife technology for extracorporeal renal tissue ablation. Urology 61 (2003) 498-501
35. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell, renal-cell carcinoma. NEJM 356 (2007) 125-134
36. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multi-targeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
37. Motzer R.J., Rini B.I., Michaelson M.D., et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 23 (2005) 4508
38. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib vs. interferon-α in metastatic renal-cell carcinoma. NEJM 356 (2007) 115-124
39. Escudier B., Szczylik C., Demkow T., et al. Randomized phase II trial of multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment-naïve patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 Suppl I (2006) 217s
40. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434